English-language podcasts

Biotech Hangout

Episode 204 - November 20, 2026

60 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

On this week’s episode, Graig Suvannavejh, Tim Opler, BrianSkorney, Chris Garabedian, and Matt Gline opened with a look at the biotech market, with the XBI up roughly 17% to 18% year to date, though the group noted that AI-driven demand for capital and the possibility of an AI bubble are weighing on sentiment. The co-hosts then discussed expectations for 2027 as a significant M&A year, following conversations with pharma M&A leaders at the Jefferies Global Healthcare Conference. The group also covered the withdrawal of Heidi Overton’s FDA Commissioner nomination and what the uncertainty could mean for agency stability and volatility. Next, they discussed market rumors of a potential Sanofi acquisition of Insmed, including Brinsupri’s performance and raised guidance, and what a deal of that size could signal for the broader M&A landscape. The group also covered Lilly’s oncology deals with Stipple Bio and Calytrix, and the growing opacity of biobucks headlines and undisclosed upfront payments. Looking ahead, they considered how AI and drug development in China could push US biotech to reinvent itself. The episode closed with SELLAS’ positive Phase 3 data for its off-the-shelf cancer vaccine and the questions that remain around the data. *This episode aired on November 20, 2026.

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Biotech Hangout

Biotech Hangout

Episode 203 - November 13, 2026

62 min

On this week’s episode, Eric Schmidt, Yaron Werber, Paul Matteis, and Kate Haviland opened with a look at the biotech market, with the XBI up roughly 25% year to date, though it feels much worse to many buy-side clients. The group discussed the midterm elections, weighing a potential blue wave against a market pricing in two more rate hikes. They also previewed next week’s Senate vote on Dr. Heidi Overton’s nomination as FDA commissioner, with Paul sharing his conversation with former FDA Commissioner Scott Gottlieb at the Stifel Healthcare Conference, where Gottlieb expressed optimism about her confirmation and her grasp of the agency’s need to rehire and rebuild expertise. The co-hosts then discussed the longer-term future of MFN deals, including sunset provisions and the question of whether the policy returns. The conversation turned to drug launches, covering how companies set expectations through pre-launch conversations with clinicians, office staff, and patients, and whether exp

Discuss this episode

Biotech Hangout

Episode 202 - November 6, 2026

61 min

On this week’s episode, Brian Skorney, Paul Matteis, Yaron Werber, and Adam Feuerstein opened with a look at what the midterm results could mean for biotech, covering the macro backdrop, the FDA, and drug pricing. The conversation then turned to Vertex’s povetacicept ahead of a potential IgAN approval at the end of November, and the competitive landscape as Vertex enters a market with two formidable competitors. In earnings news, the group discussed Revolution Medicines’ strong Q3 launch sales for Rasonque, which doubled market predictions, and the safety questions and possible label changes facing Neurocrine’s Vykat. The group also covered the race for the first FDA approval of a psilocybin depression treatment, with Compass nearing NDA completion and a reported filing from the Usona Institute, as well as Novartis’ update on tumor cases in Zolgensma-treated patients. The episode closed with the Phase 3 miss for Novartis and Ionis’ pelacarsen despite significant Lp(a) reduction, and wh

Discuss this episode

Community Poll

Waste-reduction policies should make responsible choices easy for households.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

The mayor is excellent at the job—and secretly cheating on a spouse. Is that news?

A local official is effective, honest in office, and privately having an affair. A journalist can verify it but finds no misuse of public resources or direct connection to official duties.

Does private dishonesty reveal something citizens are entitled to judge?

Explore this quandary